CoChat

Cost - Effectiueness of Streptokinase for Acute Myocardial Infarction: A Combined Meta-analysis and Decision Analysis of the Effects of Infarct Location and of Likelihood of Infarction

Midgette, Andre S., Wong, John B., Beshansky, Joni R., Porath, Avi, Fleming, Craig, Pauker, Stephen G. · 1994 · Medical Decision Making
Cited by 75

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Objective: To determine the effects of infarct location and of the likelihood of infarction on the cost-effectiveness of intravenous streptokinase (IVSK) for suspected acute myocardial infarction (AMI). Design: A meta-analysis of short-term survival was combined with a simple decision tree to determine marginal cost-effectiveness ratios for different infarct locations and different likelihoods of AMI (pMI). Setting: Six randomized trials comparing IVSK with conservative treatment. Patients: 31,940 patients with onset of symptoms of AMI from four to 24 hours earlier and, with the exception of one trial, electrocardiographic abnormalities. Patients with contraindications to thrombolytic treatment such as uncontrolled hypertension were excluded. Main results: If AMI is certain, treatment with IVSK has marginal cost- effectiveness ratios for each additional life saved of $9,900, $56,600, and $28,400, respec tively, for patients with anterior, inferior, and other locations of AMI. If pMI is 50%, treatment with IVSK has marginal cost-effectiveness ratios for each additional life saved of $22,700, $131,800, and $63,100, respectively, for patients with anterior, inferior, and other locations of AMI. Conclusions: The marginal cost-effectiveness ratio for IVSK therapy of inferior infarction is six times that for anterior infarction and rises steeply as the presence of AMI becomes less certain. Assuming society is willing to pay $250,000 per life saved, IVSK therapy should be given if the chance of acute anterior infarction exceeds 7%, if the chance of inferior infarction exceeds 32%, or if the chance of infarction in other locations exceeds 17%. In patients with suspected acute myocardial infarction, IVSK saves lives and is a reasonable use of societal resources. Key words: thrombolytic therapy; acute myocardial infarction; cost-effectiveness. (Med Decis Making 1994;14:108-117)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0272989x9401400203

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 75

Metadata

Authors
Midgette, A. S., Wong, J. B., Beshansky, J. R., Porath, A., Fleming, C., & Pauker, S. G.
Venue
Medical Decision Making
Published
1994-04
Volume
14
Issue
2
Pages
108-117
ISSN
  • 0272-989X (ISSN-L)
  • 1552-681X
OpenAlex
W2039280807
Cited by
75
References
1
FWCI
3.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost - Effectiueness of Streptokinase for Acute Myocardial Infarction: A Combined Meta-analysis and Decision Analysis of the Effects of Infarct Location and of Likelihood of Infarction. https://app.cochat.ai/papers/10.1177/0272989x9401400203
The paper
Midgette, A. S., Wong, J. B., Beshansky, J. R., Porath, A., Fleming, C., & Pauker, S. G. (1994). Cost - Effectiueness of Streptokinase for Acute Myocardial Infarction: A Combined Meta-analysis and Decision Analysis of the Effects of Infarct Location and of Likelihood of Infarction. Medical Decision Making. https://doi.org/10.1177/0272989x9401400203

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.